Pharvaris oral HAE drug cuts attacks by 83% in Phase 3
Pharvaris' oral HAE drug deucrictibant XR reduced attacks by 83% in Phase 3, meeting primary and secondary endpoints. The study enrolled 85 patients across 21 countries. The drug's efficacy is comparable to leading injectable treatments. Pharvaris shares rose 7.35% on the news, and Oppenheimer raised its price target to $75.
How this was made
The 30-second read
Why it matters
The trial data narrows the efficacy gap between oral and injectable therapies, potentially reshaping the market.
Market read
First‑report Phase 3 results with strong efficacy and immediate price reaction make this a high‑impact biotech news item.
What to watch
Regulatory timeline and reimbursement negotiations could delay revenue realization.
Background
HAE is a rare disorder treated with injectable prophylactics; oral options are limited.
Ticker impact
Pharvaris announced Phase 3 data showing an 83% reduction in HAE attacks, driving a 7.35% share rise.
Expect further upside as investors price in potential FDA approval and market share gains.
First‑report Phase 3 results, strong efficacy, and immediate share reaction indicate material upside potential.
Market effects
Oral prophylactic market for HAE may see increased competition and higher valuations for biotech peers.
European biotech sector could benefit from renewed investor interest.
Potential shift in HAE treatment landscape worldwide.
Counterpoint
Efficacy may not translate to commercial success if safety concerns or pricing issues arise.
Key entities
- companyPharvaris plc
Biotech developing oral HAE drug deucrictibant XR.
